ClinicalTrials.gg

Program

LAE102

A development code. Also written as “LAE102 intravenous administration”, “LAE102 subcutaneous administration” and “LAE102 multiple subcutaneous administration”.

Its studies are mostly in Overweight · Obesity, led by Laekna.

Furthest: phase 1, since Jun 3, 20243 company-led studies, 2 open or runningNext primary completion: Jun 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Laekna32 open or runningphase 1since Jun 3, 2024Jun 3, 2024Jun 30, 2027phase 1 · NCT06493084

Also a collaborator on its studies: Eli Lilly.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 3, 2024First study: phase 1 study in OverweightFirst studyNCT06493084 · 160 enrolled · China
  2. Mar 27, 2025Phase 1 study in PostmenopausalNCT06908707 · 32 enrolled · United States
  3. Nov 13, 2025Phase 1 study in OverweightNCT07230496 · 104 planned · Australia

Ahead

  1. Jun 30, 2027Primary completion: phase 1 study in OverweightNCT06493084
  2. Mar 20, 2028Primary completion: phase 1 study in OverweightNCT07230496

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07230496Overweight · Australia1RecruitingMar 20, 2028104
NCT06908707Postmenopausal · United States1CompletedOct 23, 202532
NCT06493084Overweight · China1Active, not recruitingJun 30, 2027160

How it is read

Names in the registry

  • “LAE102 intravenous administration”, 1 entry
  • “LAE102 subcutaneous administration”, 1 entry
  • “LAE102 multiple subcutaneous administration”, 1 entry
  • “LAE102 injection in combined with LAE103 injection”, 1 entry
  • “LAE102 SC”, 1 entry

Codes read as this program: LAE102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
LAE102 (Laekna): development program | ClinicalTrials.gg